Cardiac toxicity of high-dose chemotherapy

Bone Marrow Transplantation

Volumn 35, Issue 4, 2005, Pages 323-334

  Morandi, Paolo ^a   Ruffini, P A ^b   Benvenuto, G M ^a   Raimondi, R ^a   Fosser, V ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiotoxicity; Diagnosis; High dose chemotherapy; Review; Risk factors

Indexed keywords

ANTHRACYCLINE; ANTIARRHYTHMIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; LIPOSOME; MELPHALAN; MITOXANTRONE; MYOSIN ANTIBODY IN 111; RAZOXANE; THIOTEPA; TROPONIN;

AGE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART TAMPONADE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG CONGESTION; MEDICAL EXAMINATION; OBESITY; OLIGURIA; PERICARDITIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SCINTIANGIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; ELECTROCARDIOGRAPHY; HEART DISEASES; HUMANS; RISK FACTORS;

EID: 14644439280     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704763     Document Type: Review

References (135)

1. Craddock C. Haemopoietic stem-cell transplantation: recent progress and future promise. Lancet Oncol 2000; 1: 227-234.
2. Urbano-Ispizua A, Schmitz N, de Witte T et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002; 29: 639-646.
3. Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637-642.
4. Brodsky RA, Sensenbrenner LL, Smith BD et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001; 135: 477-483.
5. Storb R, Blume KG, O'Donnell MR et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39-44.
6. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
7. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336 1290-1297.
8. Morandi P, Ruffini PA, Benvenuto GM et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant 2001; 28: 277-282.
9. Ghielmini M, Zappa F, Menafoglio A et al. The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic. Ann Oncol 1999; 10: 533-537.
10. Cazin B, Gorin NC, Laporte JP et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-2069.
11. Santos GW, Sensenbrenner LL, Burke PJ et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc 1972; 4: 559-564.
12. Appelbaum F, Strauchen JA, Graw Jr RG et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1: 58-62.
13. Mullins GM, Anderson PN, Santos GW. High-dose cyclophosphamide therapy in solid tumors. Therapeutic, toxic and immunosuppressive effects. Cancer 1975; 36: 1950-1958.
14. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature. Cancer 1979; 43: 2223-2226.
15. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
16. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118.
17. Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
18. Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-1223.
19. Baello EB, Ensberg ME, Ferguson DW et al. Effect of high-dose cyclophosphamide and total-body irradiation on left ventricular function in adult patients with leukemia undergoing allogeneic bone marrow transplantation. Cancer Treat Rep 1986; 70: 1187-1193.
20. Lee CK, Harman GS, Hohl RJ, Gingrich RD. Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplant 1996; 18: 573-577.
21. Buckner CD, Clift RA, Fefer A et al. Aplastic anemia treated by marrow transplantation. Transplant Proc 1973; 5: 913-916.
22. Steinherz LJ, Steinherz PG, Mangiacasale D et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981; 9 417-422.
23. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: serial changes in left ventricular size, mass and performance. J Intern Med 1990; 227: 259-266.
24. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5: 91-98.
25. Gianni AM, Siena S, Bregni M et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997; 15: 2312-2321.
26. Petros WP, Broadwater G, Berry D et al. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002; 8: 698-705.
27. Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996; 14: 1484-1494.
28. Nieto Y, Cagnoni PJ, Bearman SI et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 2000; 6: 198-203.
29. Kallianpur A. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? Bone Marrow Transplant 2004; in: press.
30. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
31. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.
32. Hortobagyi GN, Buzdar AU, Theriault RL et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92 225-233.
33. Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
34. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17-26.
35. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342: 1069-1076.
36. Willemze R, Zwaan FE, Colpin G, Keuning JJ. High- dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 1982; 29: 141-146.
37. Stamatopoulos K, Kanellopoulou G, Vaiopoulos G et al. Evidence for sinoatrial blockade associated with high dose cytarabine therapy. Leukemia Res 1998; 22: 759-761.
38. Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med 1984; 144: 1868-1869.
39. Nakamae H, Tsumura K, Hino M et al. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000; 355: 805-806.
40. Trigg ME, Finlay JL, Bozdech M, Gilbert E. Fatal cardiac toxicity in bone marrow transplant patients receiving cytosine arabinoside, cyclophosphamide, and total body irradiation. Cancer 1987; 59: 38-42.
41. Petersen FB, Appelbaum FR, Buckner CD et al. Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancy. Bone Marrow Transplant 1988; 3: 619-624.
42. Kanda Y, Matsumura T, Maki K et al. Fatal cardiac toxicity in two patients receiving same-day administration of cyclophosphamide and cytarabine as conditioning for hematopoietic stem cell transplantation. Haematologica 2001; 86: 1002-1003.
43. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
44. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22-30.
45. Vose JM, Sharp G, Chan WC et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20: 2344-2352.
46. van Besien K, Tabocoff J, Rodriguez M et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995; 15: 549-555.
47. Gralow JR, Livingston RB. University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: unexpected cardiac toxicity. J Clin Oncol 2001; 19: 3903-3904.
48. Dazzi C, Cariello A, Rosti G et al. Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study. Haematologica 2001; 86: 523-529.
49. Mulder PO, Sleijfer DT, Willemse PH et al. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 1989; 49: 4654-4658.
50. Tarella C, Zallio F, Caracciolo D et al. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia 2001; 15: 256-263.
51. Attal M, Canal P, Schlaifer D et al. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 141-148.
52. Damon LE, Wolf JL, Rugo HS et al. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 2000; 26: 257-268.
53. Stiff PJ, McKenzie RS, Alberts DS et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J Clin Oncol 1994; 12: 176-183.
54. Alidina A, Lawrence D, Ford LA et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biol Blood Marrow Transplant 1999; 5: 322-327.
55. Bengala C, Pazzagli I, Innocenti F et al. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). Ann Oncol 2001; 12: 69-74.
56. Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989; 24: 395-396.
57. Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31-36.
58. Kanj SS, Sharara AI, Shpall EJ et al. Myocardial ischemia associated with high-dose carmustine infusion. Cancer 1991; 68: 1910-1912.
59. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
60. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
61. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and amologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
62. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796-2802.
63. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786-1799.
64. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
65. Olivieri A, Corvatta L, Montanari M et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients auto-transplanted with blood progenitor cells. Bone Marrow Transplant 1998; 21: 1049-1053.
66. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23 1003-1006.
67. Phillips GL, Meisenberg B, Reece DE et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004; 10: 473-483.
68. Spriano M, Clavio M, Carrara P et al. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. Haematologica 1994; 79: 218-224.
69. Ritchie DS, Seymour JF, Roberts AW et al. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001; 28: 101-103.
70. Van Besien K, Devine S, Wickrema A et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003; 32: 471-476.
71. Martino R, Caballero MD, Canals C et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659.
72. Cavet J, Lennard A, Gascoigne A et al. Constrictive pericarditis post allogeneic bone marrow transplant for Philadelphia-positive acute lymphoblastic leukaemia. Bone Marrow Transplant 2000; 25: 571-573.
73. ACC/AHA guidelines for the evaluation and the management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001; 38: 2101-2113.
74. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. Heart Failure Society of America. Pharmacotherapy 2000; 26: 1376-1398.
75. Ramrakha PS, Marks DI, O'Brien SG et al. Orthotopic cardiac transplantation for dilated cardiomyopathy after allogencic bone marrow transplantation. Clin Transplant 1994; 8: 23-26.
76. Bearman SI, Petersen FB, Schor RA et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173-177.
77. Fujimaki K, Maruta A, Yoshida M et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001; 27: 307-310.
78. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 1991; 42: 781-795.
79. Lehmann S, Isberg B, Ljungman P, Paul C. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 187-192.
80. Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000; 25: 885-894.
81. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
82. Kremer LC, van der Pal HJ, Offringa M et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13: 819-829.
83. Meinardi MT, Van Der Graaf WT, Gietema JA et al. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart 2002; 88: 81-82.
84. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
85. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-2903.
86. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130: 1-7.
87. Safra T. Cardiac afety of liposomal anthracyclines. Oncologist 2003; 8 (Suppl 2): 17-24.
88. Adams MJ, Lipshultz SE, Schwartz C et al. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 2003; 13: 346-356.
89. Auner HW, Tinchon C, Brezinschek RI et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002; 69: 1-6.
90. Carlson K, Backlund L, Smedmyr B et al. Pulmonary function and complications subsequent to autologous bone marrow transplantation. Bone Marrow Transplant 1994; 14: 805-811.
91. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-1327.
92. Powis G, Reece P, Ahmann DL, Ingle JN. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 1987; 20: 219-222.
93. Lind MJ, Margison JM, Cerny T et al. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 1989; 25: 139-142.
94. Grigg A, Harun MH, Szer J. Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. Leukemia Lymphoma 1997; 25: 487-491.
95. Dickson TM, Kusnierz-Glaz CR, Blume KG et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 299-305.
96. Navarro WH. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003; 31: 961-966.
97. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-522.
98. Akahori M, Nakamae H, Hino M et al. Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant 2003; 31: 585-590.
99. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709.
100. Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998-1004.
101. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998; 16: 3796-3802.
102. Rose M, Lee FA, Gollerkeri A et al. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplant 2000; 26: 133-139.
103. Kakavas PW, Ghalie R, Parrillo JE et al. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant 1995; 15: 859-861.
104. Zangari M, Henzlova MJ, Ahmad S et al. Predictive value of left ventricular ejection fraction in stem cell transplantation. Bone Marrow Transplant 1999; 23: 917-920.
105. Jain B, Floreani AA, Anderson JR et al. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transplant 1996; 17: 561-568.
106. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 2001; 28: 283-287.
107. Nakamae H, Hino M, Akahori M et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol 2004; 76 1-7.
108. Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002; 13: 503-512.
109. Rovelli A, Pezzini C, Silvestri D et al. Cardiac and respiratory function after bone marrow transplantation in children with leukaemia. Bone Marrow Transplant 1995; 16: 571-576.
110. Benvenuto GM, Ometto R, Fontanelli A et al. Chemotherapy related cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J 2003; 4: 655-667.
111. Ritchie JL, Bateman TM, Bonow RO et al. Guidelines for clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on Radionuclide Imaging) - developed in collaboration with the American Society of Nuclear Cardiology. J Nucl Cardiol 1995; 2: 172-192.
112. Steinherz LJ, Graham T, Hurwitz R et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942-949.
113. Basser RL, Abraham R, To LB et al. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Ann Oncol 1999; 10: 53-58.
114. Lele SS, Durrant ST, Atherton JJ et al. Demonstration of late cardiotoxicity following bone marrow transplantation by assessment of exercise diastolic filling characteristics. Bone Marrow Transplant 1996; 17: 1113-1118.
115. Suzuki J, Yanagisawa A, Shigeyama T et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology 1999; 50: 37-45.
116. Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343 1139-1147.
117. Herman EH, Zhang J, Lipshultz SE et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237-2243.
118. Kremer LC, van Dalen EC, Offringa M et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191-196.
119. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754.
120. Erselcan T, Kairemo KJ, Wiklund TA et al. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Br J Cancer 2000; 82: 777-781.
121. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
122. Nousiainen T, Jantunen E, Vanninen E et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999; 62: 135-141.
123. Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228-234.
124. Kazanegra R, Cheng V, Garcia A et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001; 7: 21-29.
125. Fleming SM, O'Gorman T, O'Byrne L et al. Cardiac troponin I and N-terminal pro-brain natriuretic peptide in umbilical artery blood in relation to fetal heart rate abnormalities during labor. Pediatr Cardiol 2001; 22: 393-396.
126. Snowden JA, Hill GR, Hunt P et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-313.
127. Niwa N, Watanabe E, Hamaguchi M et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001; 80: 460-465.
128. Appelbaum FR. Hammering away at solid tumors. Cancer Treat Rep 1987; 71: 115-117.
129. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
130. Feneley M, Lim CA. Cardiac complications. In: Atkinson K (ed.). Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge University Press: London, 2000, pp 952-957.
131. Leahey AM, Teunissen H, Friedman DL et al. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 1999; 32: 163-169.
132. Leung W, Hudson MM, Strickland DK et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000; 18: 3273-3279.
133. Liesner RJ, Leiper AD, Hann IM, Chessells JM. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994; 12: 916-924.
134. Pihkala J, Saarinen UM, Lundstrom U et al. Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant 1994; 13: 149-155.
135. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.